Intestinal Research

Original Article

IBD

Real-world use of biologics during the first year of treatment for newly diagnosed Crohn’s disease in Japan: a claims analysis from 2010 to 2021: Jun Miyoshi, Annabelle Yoon, Minoru Matsuura, Tadakazu Hisamatsu; Intest Res 2026;24(1):129-140. Published online January 23, 2025; DOI: https://doi.org/10.5217/ir.2024.00082

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Crohn’s disease (CD) leads to bowel damage and disability if suboptimally treated. We investigated firstyear treatment decisions and real-world use of biologics in patients with CD in Japan.
Methods
In this retrospective observational study (2010–2021) from the JMDC claims database, patients with a new diagnosis of CD (no CD claims record within 12 months before index) who received ≥ 1 pre-defined treatment were grouped by use of biologics and systemic corticosteroids (SCS) within the first year of diagnosis.
Results
Of 823 patients included, 470 (57.1%) were prescribed biologics and 353 (42.9%) were not; 77.6% were male, 75.7% had adult-onset CD, and median age was 24 years. Patients prescribed biologics were younger (median: 23 years vs. 28 years) and more had perianal lesions (43.0% vs. 22.9%) than those not prescribed biologics; 64.9% (95% confidence interval, 60.4%–69.2%) received a top-down treatment approach (no SCS before biologics). Factors significantly associated with a top-down treatment approach were male sex, perianal lesions, no use of immunomodulators, and use of anti-tumor necrosis factor therapies. The proportion of patients receiving SCS before biologics (step-up approach) increased after 2018, with a shift from prednisolone to budesonide from 2016. Persistence with first biologics decreased over time, with no differences between biologic types.
Conclusions
Use of biologics for treatment of CD within the first year of diagnosis in Japan has remained stable over the past decade. However, there was a shift to a step-up treatment approach, with an increase in use of SCS before biologics over time.

Citations

Citations to this article as recorded by

Towards an Asian paradigm of inflammatory bowel disease management: A comparative review of China and Japan
Qi Sun, Zhixian Jiang, Lichao Yang, Hao Liu, Peipei Song, Lianwen Yuan
Intractable & Rare Diseases Research.2025; 14(3): 192. CrossRef

5,912 View
423 Download
2 Web of Science
1 Crossref

Case Report

Fecal microbiota transplantation for refractory Crohn's disease: Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho; Intest Res 2017;15(2):244-248. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.244

Abstract PDF PubReader ePub

Approximately one-third of patients with Crohn's disease do not respond to conventional treatments, and some experience significant adverse effects, such as serious infections and lymphoma, and many patients require surgery due to complications. Increasing evidence suggests that specific changes in the composition of gut microbiota, termed as dysbiosis, are a common feature in patients with inflammatory bowel disease (IBD). Dysbiosis can lead to activation of the mucosal immune system, resulting in chronic inflammation and the development of mucosal lesions. Recently, fecal microbiota transplantation, aimed at modifying the composition of gut microbiota to overcome dysbiosis, has become a potential alternative therapeutic option for IBD. Herein, we present a patient with Crohn's colitis in whom biologic therapy failed previously, but clinical remission and endoscopic improvement was achieved after a single fecal microbiota transplantation infusion.

Citations

Citations to this article as recorded by

Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn’s disease
Yao Xu, Runxiang Xie, Yuqing Weng, Yewei Fang, Shuan Tao, He Zhang, Huimin Chen, Axiang Han, Qi Jiang, Wei Liang
International Journal of Colorectal Disease.2025;[Epub] CrossRef
Epigenetics and the role of nutraceuticals in health and disease
Amr El-Sayed, Lotfi Aleya, Mohamed Kamel
Environmental Science and Pollution Research.2023; 30(11): 28480. CrossRef
Crohn’s disease: Etiology, pathogenesis and treatment strategies
Izel Aycan BASOGLU, Berna KARAKOYUN
Marmara Medical Journal.2023; 36(2): 249. CrossRef
Alteration of microbiota antibody‐mediated immune selection contributes to dysbiosis in inflammatory bowel diseases
Eva Michaud, Louis Waeckel, Rémi Gayet, Roman Goguyer‐Deschaumes, Blandine Chanut, Fabienne Jospin, Katell Bathany, Magali Monnoye, Coraline Genet, Amelie Prier, Caroline Tokarski, Philippe Gérard, Xavier Roblin, Nicolas Rochereau, Stéphane Paul
EMBO Molecular Medicine.2022;[Epub] CrossRef
Gut microbiota: A new target for T2DM prevention and treatment
Lulu Liu, Jiheng Zhang, Yi Cheng, Meng Zhu, Zhifeng Xiao, Guangcong Ruan, Yanling Wei
Frontiers in Endocrinology.2022;[Epub] CrossRef
Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Cátia Almeida, Rita Oliveira, Pilar Baylina, Rúben Fernandes, Fábio G. Teixeira, Pedro Barata
Biomedicines.2022; 10(11): 2742. CrossRef
Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021
Fengwei Zhang, Peilin Yang, Yilin Chen, Ruirui Wang, Baocheng Liu, Jianying Wang, Min Yuan, Lei Zhang
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis
F. Cheng, Z. Huang, W. Wei, Z. Li
Techniques in Coloproctology.2021; 25(5): 495. CrossRef
Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intestinal Research.2021; 19(3): 265. CrossRef
Microbiota and epigenetics: promising therapeutic approaches?
Amr El-Sayed, Lotfi Aleya, Mohamed Kamel
Environmental Science and Pollution Research.2021; 28(36): 49343. CrossRef
Improving the Gut Microbiota with Probiotics and Faecal Microbiota Transplantation
Yogita M. Patil, Rajashree B. Patwardhan, Pragati S. Abhyankar
Journal of Pure and Applied Microbiology.2021; 15(3): 1111. CrossRef
Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
Yonghyun Lee, Nobuhiko Kamada, James J. Moon
Advanced Drug Delivery Reviews.2021; 179: 114021. CrossRef
Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview
Donghun Oh, Keun-Ah Cheon
Journal of the Korean Academy of Child and Adolescent Psychiatry.2020; 31(3): 131. CrossRef
Development of the Korean Form of the Premonitory Urge for Tics Scale: A Reliability and Validity Study
Mira Kim, Sang-Keun Chung, Jong-Chul Yang, Jong-Il Park, Seok Hyun Nam, Tae Won Park
Journal of the Korean Academy of Child and Adolescent Psychiatry.2020; 31(3): 146. CrossRef
Secondary causes of inflammatory bowel diseases
Yezaz A Ghouri, Veysel Tahan, Bo Shen
World Journal of Gastroenterology.2020; 26(28): 3998. CrossRef
Fecal microbiota transplantation in the treatment of Crohn disease
Miranda Collins, Morgan DeWitt
JAAPA.2020; 33(9): 34. CrossRef
Inflammatory Bowel Diseases: The Role of Gut Microbiota
Cristiana De Musis, Lucia Granata, Marcello Dallio, Agnese Miranda, Antonietta G. Gravina, Marco Romano
Current Pharmaceutical Design.2020; 26(25): 2951. CrossRef
The human-microbiome superorganism and its modulation to restore health
E. Salvucci
International Journal of Food Sciences and Nutrition.2019; 70(7): 781. CrossRef
The microbiome, cancer, and cancer therapy
Beth A. Helmink, M. A. Wadud Khan, Amanda Hermann, Vancheswaran Gopalakrishnan, Jennifer A. Wargo
Nature Medicine.2019; 25(3): 377. CrossRef
RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef
Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery
Michael Kriss, Keith Z Hazleton, Nichole M Nusbacher, Casey G Martin, Catherine A Lozupone
Current Opinion in Microbiology.2018; 44: 34. CrossRef
Microbiota transplantation: concept, methodology and strategy for its modernization
Faming Zhang, Bota Cui, Xingxiang He, Yuqiang Nie, Kaichun Wu, Daiming Fan
Protein & Cell.2018; 9(5): 462. CrossRef
The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies
Gabriel M. Alexandre-Silva, Pablo A. Brito-Souza, Ana C.S. Oliveira, Felipe A. Cerni, Umberto Zottich, Manuela B. Pucca
Acta Tropica.2018; 188: 16. CrossRef
The Safety of Fecal Microbiota Transplantation for Crohn’s Disease: Findings from A Long-Term Study
Honggang Wang, Bota Cui, Qianqian Li, Xiao Ding, Pan Li, Ting Zhang, Xiaozhong Yang, Guozhong Ji, Faming Zhang
Advances in Therapy.2018; 35(11): 1935. CrossRef
Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef
Diagnosis and treatment of Crohn's disease
Hyun-Soo Kim
Journal of the Korean Medical Association.2017; 60(6): 484. CrossRef

8,429 View
71 Download
25 Web of Science
26 Crossref

First
Prev
Page of 1
Next
Last

Search